Eukaryotic Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Homo sapiens (Human) Eukaryotic protein

CD309; FLK1; VEGFR; KDR; A Type III Receptor Tyrosine Kinase; Kinase Insert Domain Receptor; Kinase Insert Domain Receptor; Fetal Liver Kinase-1

Add to Cart Distributors
Overview
Properties
  • Source Eukaryotic expression, Host 293F cell
  • Endotoxin Level<1.0EU per 1ug (determined by the LAL method)
  • Subcellular LocationMembrane, Nucleus, Secreted, Cytoplasm, Endoplasmic reticulum lumen, Endosome
  • Molecular Mass 84.9kDa, Accurate 90kDa(Analysis of differences refer to the manual)
  • Residues & TagsAla20~Glu764 with N-terminal His Tag
  • Buffer FormulationPBS, pH7.4, containing 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 95%
  • Isoelectric Point6.1
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Eukaryotic Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Packages (Simulation)
  • Eukaryotic Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Packages (Simulation)
  • Eukaryotic Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Figure . Gene Sequencing (extract)
  • EPB367Hu61.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Sequence

Usage

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathwayPubMed: 23398358
  • Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: an in vitro osteoblast-osteoclast-endothelial cell co-culture studyPubMed: 26689470
  • Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: An in vitro osteoblast–osteoclast–endothelial cell co-culture studyPubmed:26689470
  • A Human 3D In Vitro Model to Assess the Relationship Between Osteoporosis and Disseminationto Bone of Breast Cancer Tumor Cells.pubmed:27925188
  • The directional migration and differentiation of mesenchymal stem cells toward vascular endothelial cells stimulated by biphasic calcium phosphate ceramic10.1093/rb/rbx028
  • VEGF-R2 and TNF-R1 expression and cytokine production by samples of mammary adenocarcinomas and correlations with histopathological parameters of these …Pubmed:29985074
  • Effect of isotretinoin (13-cis-retinoic acid) on levels of soluble VEGF receptors (sVEGFR1, sVEGFR2, sVEGFR3) in patients with acne vulgarisPubmed: 32043381
  • Encapsulated VEGF 121-PLA microparticles promote angiogenesis in human endometrium stromal cells33523322
  • Intuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy34324118
  • Effect of subacute poisoning with lambdacyhalothrin on vascular endothelial growth factor 2 receptor in mice kidneysPubmed:35643467

Recommend products